Saturday, June 20, 2026
No article body is available. The title mentions Amgen and FDA staffing changes, but no peptide-specific facts can be confirmed.
Novo Nordisk rebranded its pill form of semaglutide, calling it the Ozempic pill instead of Rybelsus. Amgen cut back some of its drug projects.
Novo wants people to know Rybelsus is the same drug as Ozempic, just in pill form. That could help pill sales as oral weight-loss drugs heat up.
Amgen started three big trials for MariTide, its obesity drug. One trial will test MariTide in patients switching away from rival weight-loss drugs made by Eli Lilly and Novo Nordisk.
Amgen wants to prove MariTide works for people who quit Ozempic or Zepbound. A win could pull patients away from Lilly and Novo.
Amgen is marketing MariTide, its new weight-loss drug, as a monthly injection option that could work better than competitors. The company is positioning it as a choice for people who want fewer injections and potentially better results.
Amgen wants MariTide to stand out by needing only one shot a month. Most rival weight-loss shots are weekly, so this could appeal to people tired of frequent jabs.
Amgen is pushing harder into the weight-loss drug race. That could mean more competition for Novo and Lilly down the road.